Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Paolo A. Ascierto, James Larkin, Claus Garbe et al.|The Lancet Oncology|2016

Cited by 1k